vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and i3 Verticals, Inc. (IIIV). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $52.7M, roughly 1.5× i3 Verticals, Inc.). i3 Verticals, Inc. runs the higher net margin — 0.9% vs -9.6%, a 10.5% gap on every dollar of revenue. On growth, i3 Verticals, Inc. posted the faster year-over-year revenue change (-14.6% vs -16.8%). Over the past eight quarters, i3 Verticals, Inc.'s revenue compounded faster (-4.7% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

The Prusa i3 is a family of fused filament fabrication 3D printers, manufactured by Czech company Prusa Research under the trademarked name Original Prusa i3. Part of the RepRap project, Prusa i3 printers were called the most used 3D printer in the world in 2016. The first Prusa i3 was designed by Josef Průša in 2012, and was released as a commercial kit product in 2015. The latest model is available in both kit and factory assembled versions. The Prusa i3's comparable low cost and ease of co...

BIOX vs IIIV — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.5× larger
BIOX
$77.6M
$52.7M
IIIV
Growing faster (revenue YoY)
IIIV
IIIV
+2.2% gap
IIIV
-14.6%
-16.8%
BIOX
Higher net margin
IIIV
IIIV
10.5% more per $
IIIV
0.9%
-9.6%
BIOX
Faster 2-yr revenue CAGR
IIIV
IIIV
Annualised
IIIV
-4.7%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BIOX
BIOX
IIIV
IIIV
Revenue
$77.6M
$52.7M
Net Profit
$-7.4M
$484.0K
Gross Margin
46.8%
Operating Margin
9.3%
3.1%
Net Margin
-9.6%
0.9%
Revenue YoY
-16.8%
-14.6%
Net Profit YoY
-20.2%
-76.5%
EPS (diluted)
$-0.12
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
IIIV
IIIV
Q4 25
$52.7M
Q3 25
$77.6M
$46.0M
Q2 25
$51.9M
Q1 25
$60.6M
$63.1M
Q4 24
$98.8M
$52.2M
Q3 24
$93.3M
$32.0M
Q2 24
$46.2M
Q1 24
$84.0M
$58.0M
Net Profit
BIOX
BIOX
IIIV
IIIV
Q4 25
$484.0K
Q3 25
$-7.4M
$3.1M
Q2 25
$12.9M
Q1 25
$-1.6M
$-154.0K
Q4 24
$605.2K
$2.1M
Q3 24
$-6.2M
$117.9M
Q2 24
$-7.5M
Q1 24
$9.8M
$1.9M
Gross Margin
BIOX
BIOX
IIIV
IIIV
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Operating Margin
BIOX
BIOX
IIIV
IIIV
Q4 25
3.1%
Q3 25
9.3%
3.2%
Q2 25
-9.3%
Q1 25
1.5%
8.0%
Q4 24
14.5%
3.9%
Q3 24
2.5%
10.6%
Q2 24
-2.8%
Q1 24
15.7%
3.4%
Net Margin
BIOX
BIOX
IIIV
IIIV
Q4 25
0.9%
Q3 25
-9.6%
6.7%
Q2 25
24.8%
Q1 25
-2.6%
-0.2%
Q4 24
0.6%
3.9%
Q3 24
-6.6%
368.2%
Q2 24
-16.3%
Q1 24
11.6%
3.2%
EPS (diluted)
BIOX
BIOX
IIIV
IIIV
Q4 25
$0.02
Q3 25
$-0.12
$0.14
Q2 25
$0.50
Q1 25
$-0.02
$0.00
Q4 24
$0.00
$0.08
Q3 24
$-0.10
$4.93
Q2 24
$-0.32
Q1 24
$0.14
$0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
IIIV
IIIV
Cash + ST InvestmentsLiquidity on hand
$15.5M
$37.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$358.5M
Total Assets
$734.9M
$595.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
IIIV
IIIV
Q4 25
$37.5M
Q3 25
$15.5M
$66.7M
Q2 25
$55.5M
Q1 25
$38.5M
$7.7M
Q4 24
$29.2M
$85.6M
Q3 24
$32.3M
$86.5M
Q2 24
$9.7M
Q1 24
$16.4M
$3.1M
Total Debt
BIOX
BIOX
IIIV
IIIV
Q4 25
Q3 25
$0
Q2 25
$0
Q1 25
$12.0M
Q4 24
$26.2M
Q3 24
$26.2M
Q2 24
$374.1M
Q1 24
$369.6M
Stockholders' Equity
BIOX
BIOX
IIIV
IIIV
Q4 25
$358.5M
Q3 25
$288.3M
$389.6M
Q2 25
$383.3M
Q1 25
$345.0M
$385.2M
Q4 24
$346.3M
$375.0M
Q3 24
$346.0M
$379.7M
Q2 24
$249.7M
Q1 24
$348.5M
$249.3M
Total Assets
BIOX
BIOX
IIIV
IIIV
Q4 25
$595.9M
Q3 25
$734.9M
$638.4M
Q2 25
$623.3M
Q1 25
$798.2M
$646.4M
Q4 24
$835.2M
$726.2M
Q3 24
$827.3M
$730.7M
Q2 24
$861.7M
Q1 24
$836.1M
$625.8M
Debt / Equity
BIOX
BIOX
IIIV
IIIV
Q4 25
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.03×
Q4 24
0.07×
Q3 24
0.07×
Q2 24
1.50×
Q1 24
1.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
IIIV
IIIV
Operating Cash FlowLast quarter
$14.4M
$14.1M
Free Cash FlowOCF − Capex
$13.8M
FCF MarginFCF / Revenue
26.2%
Capex IntensityCapex / Revenue
0.6%
Cash ConversionOCF / Net Profit
29.18×
TTM Free Cash FlowTrailing 4 quarters
$6.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
IIIV
IIIV
Q4 25
$14.1M
Q3 25
$14.4M
$14.0M
Q2 25
$7.4M
Q1 25
$23.3M
$-27.1M
Q4 24
$-5.4M
$11.5M
Q3 24
$5.2M
$15.1M
Q2 24
$8.1M
Q1 24
$-17.4M
$10.7M
Free Cash Flow
BIOX
BIOX
IIIV
IIIV
Q4 25
$13.8M
Q3 25
$13.5M
Q2 25
$6.8M
Q1 25
$-27.6M
Q4 24
$11.0M
Q3 24
$14.6M
Q2 24
$7.2M
Q1 24
$9.9M
FCF Margin
BIOX
BIOX
IIIV
IIIV
Q4 25
26.2%
Q3 25
29.5%
Q2 25
13.1%
Q1 25
-43.8%
Q4 24
21.1%
Q3 24
45.6%
Q2 24
15.6%
Q1 24
17.1%
Capex Intensity
BIOX
BIOX
IIIV
IIIV
Q4 25
0.6%
Q3 25
0.9%
Q2 25
1.0%
Q1 25
0.8%
Q4 24
0.9%
Q3 24
1.7%
Q2 24
1.9%
Q1 24
1.4%
Cash Conversion
BIOX
BIOX
IIIV
IIIV
Q4 25
29.18×
Q3 25
4.52×
Q2 25
0.57×
Q1 25
Q4 24
-8.85×
5.59×
Q3 24
0.13×
Q2 24
Q1 24
-1.78×
5.72×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

IIIV
IIIV

License And Service$35.7M68%
Proprietary Payments Revenue$14.5M27%
Other Revenue$2.5M5%

Related Comparisons